CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1554-1565

  Sarvi, Sana ^a   Mackinnon, Alison C ^b   Avlonitis, Nicolaos ^a,c   Bradley, Mark ^c   Rintoul, Robert C ^d   Rassl, Doris M ^d   Wang, Wei ^e   Forbes, Stuart J ^b   Gregory, Christopher D ^a   Sethi, Tariq ^e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d PAPWORTH HOSPITAL   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CD133 ANTIGEN; ETOPOSIDE; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; PEPTIDE 1; PODOPHYLLOTOXIN BENZYLIDENE GLUCOSIDE; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN KINASE B; SUBSTANCE P DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD; CARCINOGENESIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; NEUROPEPTIDES; PEPTIDES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NEUROPEPTIDE; SMALL CELL LUNG CARCINOMA;

EID: 84896517688     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1541     Document Type: Article

References (57)

1. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003;41:245-58.
2. Ferlay J, Randi G, Bosetti C, Levi F, Negri E, Boyle P, et al. Declining mortality from bladder cancer in Europe. BJU Int 2008;101:11-9.
3. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
4. Sethi T, Langdon S, Smyth J, Rozengurt E. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res 1992; 52:2737s-42s.
5. Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res 1991;51:3621-3.
6. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009;106:16281-6.
7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
8. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004;432: 396-401.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
10. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-14.
11. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5.
13. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.
14. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-50.
15. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-12.
16. Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, et al. Generation and characterisation of Cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PloS ONE 2013;8:e54193.
17. Flores DG, Ledur PF, Abujamra AL, Brunetto AL, Schwartsmann G, Lenz G, et al. Cancer stem cells and the biology of brain tumors. Curr Stem Cell Res Ther 2009;4:306-13.
18. Linnoila RI, Naizhen X, Meuwissen R, Berns A, DeMayo FJ. Mouse lung neuroendocrine carcinomas: distinct morphologies, same transcription factors. Exp Lung Res 2005;31:37-55.
19. Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev 2005;19:643-64.
20. Berns A. Stem cells for lung cancer? Cell 2005;121:811-3.
21. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823-35.
22. Waters CM, MacKinnon AC, Cummings J, Tufail-Hanif U, Jodrell D, Haslett C, et al. Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9, NmePhe8]-substance P (6-11)-induced growth inhibition. Br J Cancer 2003;88:1808-16.
23. MacKinnon AC, Tufail-Hanif U, Lucas CD, Jodrell D, Haslett C, Sethi T. Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition. Br J cancer 2005;92:522-31.
24. MacKinnon AC, Waters C, Rahman I, Harani N, Rintoul R, Haslett C, et al. [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (antagonist G) induces AP-1 transcription and sensitizes cells to chemotherapy. Br J Cancer 2000;83:941-8.
25. Berendsen HH, de Leij L, de Vries EG, Mesander G, Mulder NH, de Jong B, et al. Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res 1988;48:6891-9.
26. Lawson MH, Cummings NM, Rassl DM, Russell R, Brenton JD, Rintoul RC, et al. Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res 2011;71:4877-87.
27. Sethi T, Herget T, Wu SV, Walsh JH, Rozengurt E. CCKA and CCKB receptors are expressed in small cell lung cancer lines and mediate Ca2+ mobilization and clonal growth. Cancer Res 1993;53: 5208-13.
28. MacKinnon A, Sethi T. [D-Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism. Methods Mol Med 2003; 74:299-307.
29. Jones DA, Cummings J, Langdon SP, MacLellan AJ, Higgins T, Rozengurt E, et al. Metabolism of the anticancer peptide H-Arg-DTrp-NmePhe-D-Trp-Leu-Met-NH2. Peptides 1995;16:777-83.
30. Jones DA, Cummings J, Langdon SP, MacLellan A, Smyth JF. Characterization of the deamidase enzyme responsible for the metabolism of the anticancer peptide: H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2. Biochem Pharmacol 1995;50:585-90.
31. Clive S, Webb DJ, MacLellan A, Young A, Byrne B, Robson L, et al. Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clin Cancer Res 2001;7: 3071-8.
32. Seckl MJ, Higgins T, Widmer F, Rozengurt E. [D-Arg1,D-Trp5,7,9, Leu11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 1997;57:51-4.
33. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drugselected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PloS ONE 2008;3:e3077.
34. Tan S, Chen JS, Sun LJ, Yao HR. Selective enrichment of hepatocellular cancer stem cells by chemotherapy. J Int Med Res 2009;37: 1046-56.
35. Yang K, Chen XZ, Zhang B, Yang C, Chen HN, Chen ZX, et al. Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-Analysis. Int J Biol Markers 2011;26: 173-80.
36. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancerderived CD133-positive cells. PloS ONE 2008;3:e2637.
37. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
38. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev 2008; 8:755-68.
39. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-58.
40. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275:5512-20.
41. Corti M, Brody AR, Harrison JH. Isolation and primary culture of murine alveolar type II cells. Am J Respir Cell Mol Biol 1996;14:309-15.
42. Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV, Matsui W, et al. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res 2009;69:845-54.
43. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008;6:1146-53.
44. Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 2008;26:3027-36.
45. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 2011;104:1730-8.
46. Tallett A, Chilvers ER, MacKinnon AC, Haslett C, Sethi T. Neuropeptides stimulate tyrosine phosphorylation and tyrosine kinase activity in small cell lung cancer cell lines. Peptides 1996;17:665-73.
47. Sethi T, Rozengurt E. Galanin stimulates Ca2+ mobilization, inositol phosphate accumulation, and clonal growth in small cell lung cancer cells. Cancer Res 1991;51:1674-9.
48. Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C, et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006;13:1776-88.
49. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, Sethi T. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 1998;58:5239-47.
50. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
51. Hodkinson PS, Elliott PA, Lad Y, McHugh BJ, MacKinnon AC, Haslett C, et al. Mammalian NOTCH-1 activates beta1 integrins via the small GTPase R-Ras. J Biol Chem 2007;282:28991-9001.
52. Hodkinson PS, Mackinnon A, Sethi T. Targeting growth factors in lung cancer. Chest 2008;133:1209-16.
53. Arcaro A, Khanzada UK, Vanhaesebroeck B, Tetley TD, Waterfield MD, Seckl MJ. Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J 2002;21:5097-108.
54. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2013;229: 355-78.
55. O'Flaherty JD, Barr M, Fennell D, Richard D, Reynolds J, O'Leary J, et al. The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy. J Thorac Oncol 2012;7: 1880-90.
56. Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, et al. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Sci 2013;104:78-84.
57. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, et al. Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 2010;4:32-42.